The Joint Interagency Task Force 401 (JIATF-401) announced today it has awarded a $5.2 million agreement to Perennial ...

Dr. James McCaffrey presents a complete end-to-end demonstration of linear regression with pseudo-inverse training implemented using JavaScript. Compared to other training techniques, such as ...

3I/ATLAS has passed its closest point to Earth, meaning we will soon lose sight of it for good. Some scientists want to send a spacecraft to chase down the alien comet — or the next interstellar ...

After a long run of regulatory stumbles and the recent withdrawal of its lone commercial drug from the U.S. market, Intercept Pharmaceuticals is implementing a restructuring and rounds of job cuts in ...

Gradient Ventures has spun out of Google to better position itself to win deals in the fast-moving early-stage AI market, according to people familiar with the situation. Gradient Ventures is now ...

U.S. fighter jets scrambled Wednesday to intercept four Russian warplanes off the coast of Alaska, the North American Aerospace Defense Command (NORAD) said Thursday. NORAD said in a statement it ...

U.S. fighter jets were scrambled Wednesday to identify and intercept four Russian warplanes flying near Alaska, the North American Aerospace Defense Command said in a statement. NORAD said two Russian ...

While the path for any drug to go from lab research to commercialization takes years, Intercept Pharmaceuticals now stands as another example that a product’s market exit can also be long and winding.

Please provide your email address to receive an email when new articles are posted on . Intercept has voluntarily withdrawn its lone product, Ocaliva, from U.S. market for primary biliary cholangitis.

Sept 11 (Reuters) - Intercept Pharmaceuticals said on Thursday it is withdrawing its liver disease drug from the U.S. market following a request from the Food and Drug Administration. This comes as ...

After years of regulatory struggles for Intercept Pharmaceuticals and its liver disease drug Ocaliva (obeticholic acid), the FDA has called time on the drug's run in the U.S. market. The agency placed ...